Market News / Story
Editas upgraded at Wells Fargo as Australia approves gene editing trial
Seeking Alpha ·
Seeking Alpha reports: Editas Medicine traded higher on Thursday after Australian authorities cleared a Phase 1/2 trial for the company’s gene-editing therapy EDIT-401, and Wells Fargo upgraded the biotech to Overweight from Equal Weight in reaction. In a statement, Cambridge, Massachusetts-based Editas said that the Human Research Ethics Committee of Australia approved the initiation of its Phase 1/2 Strive trial for EDIT-401 in patients with hyperlipidemia. Strive is designed to test a…